A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-B

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (COPERNICUS)

Last Updated February 21, 2025

Want to learn how to participate in this trial?

61186372NSC2012

OVERVIEW

Sexes Eligible for Study
all
Age
18+ years
Phase
phase 2

2
Sites
7 Sites
Status

Recruiting

SUMMARY

The primary purpose of the study is to assess how well amivantamab subcutaneous (SC) administration in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC; that is one of the major types of lung cancer).

CONDITIONS

Carcinoma, Non-Small-Cell Lung

ELIGIBILITY

Inclusion Criteria:

* Have histologically or cytologically confirmed advanced or metastatic non-small cell lung cancer (NSCLC) that is not amenable to curative intent therapy
* Epidermal growth factor resistance-mutation (EGFRm) must be an Ex19del or Ex21 L858R substitution, as detected by food and drug administration (FDA)-approved or other validated test in a clinical laboratory improvement amendments (CLIA)-certified laboratory in accordance with site standard of care
* Have at least 1 measurable lesion, according to RECIST version (v)1.1, that has not been previously irradiated
* Any toxicities from prior systemic anticancer therapy must have resolved to national cancer institute common terminology criteria for adverse events (NCI-CTCAE) version 5.0 grade 1 or baseline level (except for alopecia [any grade], grade <=2 peripheral neuropathy, or grade <=2 hypothyroidism stable on hormone replacement)
* Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1

Exclusion Criteria:

* Medical history of active interstitial lung disease (ILD), including drug-induced ILD or radiation pneumonitis
* Had major surgery excluding placement of vascular access or tumor biopsy or had significant traumatic injury within 4 weeks before the first dose of anticancer treatments or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study
* Participant has uncontrolled tumor-related pain (symptomatic lesions amenable to palliative radiotherapy should be treated prior to first dosing)
* Received an investigational treatment that has not been cleared (based on at least 5 half lives of any pharmaceutical treatment) or within 12 months before the planned first dose of study treatment or is currently enrolled in an investigational study
* Has a prior or concurrent second malignancy (other than the disease under study) which natural history or treatment could likely interfere with any study endpoints of safety or the efficacy of the study treatment(s)

Inclusion Criteria:

More...

DETAILS

LOCATIONS

Locations in:

United States

Country (1)	City or Province (7)	Status
United States	Los Alamitos Cancer and Blood Specialty Clinic	RECRUITING
United States	Santa Rosa Providence Medical Foundation	RECRUITING
United States	Hinsdale Hope and Healing Cancer Services	RECRUITING
United States	Wilson Regional Medical Oncology Center	RECRUITING
United States	El Paso Renovatio Clinical	RECRUITING
United States	Kingwood Community Clinical Trials	RECRUITING
United States	The Woodlands Renovatio Clinical	RECRUITING

Geo Locations

33.80307, -118.07256

38.44047, -122.71443

41.80086, -87.93701

35.72127, -77.91554

31.75872, -106.48693

30.03355, -95.26104

30.15799, -95.48938

Indicates 50+ sites in this region: click to zoom in.

Indicates 10+ sites in this region: click to zoom in.

Indicates < 10 sites in this region: click to zoom in.

Corresponds to individual site.

Our Stories List